Médecins Sans Frontières begins brincidofovir and favipiravir trials in Ebola treatment centers in West Africa

14 November 2014

International medical humanitarian organization Médecins Sans Frontières (MSF) is to host clinical trials in three Ebola treatment centers in West Africa, aimed at quickly finding an effective therapy to be used against the disease.

Trials in Guinea

The French National Institute of Health and Medical Research will lead a trial of favipiravir, under development by Japan's Fujifilm, in Guéckédou, Guinea; the Antwerp Institute of Tropical Medicine will lead a trial of convalescent whole blood and plasma therapy in Conakry, Guinea; and the University of Oxford will lead a Wellcome Trust-funded trial of US biophama company Chimerix' (Nasdaq: CMRX) antiviral brincidofovir at an as-yet undetermined site on behalf of the International Severe Acute Respiratory and Emerging Infection Consortium.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >